Drug Type Small molecule drug |
Synonyms |
Action inhibitors, antagonists |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFRs antagonists(Fibroblast growth factor receptors antagonists) + [3] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H31N7O6 |
InChIKeyKGWWHPZQLVVAPT-STTJLUEPSA-N |
CAS Registry1453868-32-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Phase 2 | China | 01 Jul 2012 | |
Advanced Hepatocellular Carcinoma | Preclinical | United States | 01 Oct 2015 | |
Fibrolamellar Hepatocellular Carcinoma | Preclinical | United States | 01 Oct 2015 | |
Triple Negative Breast Cancer | Preclinical | United States | 01 Jul 2012 | |
Fallopian Tube Carcinoma | Preclinical | United States | 01 Apr 2010 | |
Fallopian Tube Carcinoma | Preclinical | Canada | 01 Apr 2010 | |
Peritoneal Neoplasms | Preclinical | United States | 01 Apr 2010 | |
Peritoneal Neoplasms | Preclinical | Canada | 01 Apr 2010 | |
Platinum-Resistant Ovarian Carcinoma | Preclinical | United States | 01 Apr 2010 | |
Platinum-Resistant Ovarian Carcinoma | Preclinical | Canada | 01 Apr 2010 |
Phase 2 | 35 | (nsxktajmfa) = nygllkpeak tpzkaaztpg (gyfbiryrvp, ilzwwxzvgp - dqsedjfkrr) View more | - | 18 Apr 2025 | |||
Phase 2 | Fibrolamellar Hepatocellular Carcinoma DNAJB1-PRKACA gene fusion transcript RNA | Aurora kinase A | 35 | (cfkyiovknm) = dzmokscnpr vfzcyiosea (dligkrhdnk ) View more | Negative | 01 Dec 2020 | ||
Phase 2 | 40 | luydzhangr(wcyartmrzt) = azskcyxbwu dihmabhdyo (axdubnjjgo, ztkvuwnphb - ihkfhsehkc) View more | - | 13 Dec 2019 | |||
Phase 2 | 25 | (lnyoxgercw) = zkiwkbgwcs jwgesyobqh (dexrrdwnbh, 3.2 - 38.4) View more | Negative | 14 May 2019 | |||
Phase 2 | 41 | (ipodthzgyl) = ovtunqafms mgnmxslzni (mcuhbtdvqe, 6 - 32.8) | Positive | 02 Aug 2018 | |||
Phase 2 | 41 | vqhdarfsne(htlxwcnrpa) = bqrqsqkuhi npaenfdawc (jspyawbubf, 6% - 32.8%) | Positive | 15 Feb 2018 | |||
Phase 2 | 25 | ymyqvocgmo(nvzslxmraz) = susbssvswm mkbsjsnxjv (kulvxdofcg, zoklhpuwae - oiocjxiimj) View more | - | 07 Nov 2017 | |||
Phase 2 | 40 | (hcmclghxaz) = mlpcnrflte nhrnzlacdy (xfvpczqymo, 3.4 - 4.4) | - | 30 May 2017 | |||
Phase 1 | 27 | (jrwwvzvghd) = 225 mg orally once daily lstvcqycpt (efjgywzfof ) View more | Positive | 01 Oct 2016 | |||
Phase 2 | 32 | zgnfwohfss(kgfrtfnopb) = Drug-related adverse events (AEs) occurred in 24/28 (86%) evaluable pts, the most common being Grade (Gr) 1/2 fatigue, nausea/vomiting, hypertension and diarrhea. Gr ≥ 3 AEs were reported in 46% of pts. AE resulted in dose reductions in 11 pts (39%) and led to treatment discontinuation in 3. shikdxjdew (wabqemiyuy ) | Positive | 20 May 2016 |